NCT05122221 - CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

December 31, 2024

Conditions

Cervical CancerAnal CancerHead and Neck Cancers

Interventions

DRUG

Fludarabine + Cyclophosphamide

Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days

DRUG

Interleukin-2

Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.

BIOLOGICAL

CRTE7A2-01 TCR-T Cell

On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.

Trial Locations (1)

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou